Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11874181rdf:typepubmed:Citationlld:pubmed
pubmed-article:11874181lifeskim:mentionsumls-concept:C0001779lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0029433lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0009325lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0439793lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0043603lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C1707520lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:11874181lifeskim:mentionsumls-concept:C0332162lld:lifeskim
pubmed-article:11874181pubmed:issue2lld:pubmed
pubmed-article:11874181pubmed:dateCreated2002-3-4lld:pubmed
pubmed-article:11874181pubmed:abstractTextSevere forms of osteogenesis imperfecta (OI) are characterised by osteoporosis with multiple fractures, deformity, progressive loss of mobility and chronic bone pain. Bisphosphonates, as osteoclast inhibitors, reduce bone turnover and improve osteoporosis.lld:pubmed
pubmed-article:11874181pubmed:languageenglld:pubmed
pubmed-article:11874181pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11874181pubmed:citationSubsetIMlld:pubmed
pubmed-article:11874181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11874181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11874181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11874181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11874181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11874181pubmed:statusMEDLINElld:pubmed
pubmed-article:11874181pubmed:monthFeblld:pubmed
pubmed-article:11874181pubmed:issn0334-018Xlld:pubmed
pubmed-article:11874181pubmed:authorpubmed-author:ZacharinMarga...lld:pubmed
pubmed-article:11874181pubmed:authorpubmed-author:BatemanJohnJlld:pubmed
pubmed-article:11874181pubmed:issnTypePrintlld:pubmed
pubmed-article:11874181pubmed:volume15lld:pubmed
pubmed-article:11874181pubmed:ownerNLMlld:pubmed
pubmed-article:11874181pubmed:authorsCompleteYlld:pubmed
pubmed-article:11874181pubmed:pagination163-74lld:pubmed
pubmed-article:11874181pubmed:dateRevised2006-3-8lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:meshHeadingpubmed-meshheading:11874181...lld:pubmed
pubmed-article:11874181pubmed:year2002lld:pubmed
pubmed-article:11874181pubmed:articleTitlePamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.lld:pubmed
pubmed-article:11874181pubmed:affiliationDepartment of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Victoria, Australia. zacharim@cryptic.rch.unimelb.edu.aulld:pubmed
pubmed-article:11874181pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11874181pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11874181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11874181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11874181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11874181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11874181lld:pubmed